Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting neoantigens: protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. Our approach is based on the science of tumour evolution which allows us to identify neoantigens that arise early in the cancer’s development and are retained as each tumour grows. These ‘clonal’ neoantigens are present on all the cancer cells and are completely absent from a patient’s healthy tissue. By directing T cells therapies to clonal neoantigens we can for the first time target every cancer cell without attacking healthy tissue.
Stevenage, UK 21 January 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical…Read More +
Stevenage, UK; 10 December 2018 – Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer…Read More +
Stevenage, 19 September 2018 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens, today announced that it…Read More +
Achilles Founders map truncal and branched mutations and copy number events to predict early relapse in non-small cell cancer lungs, opening…Read More +
Achilles Therapeutics starts 2017 with move to Stevenage Bioscience Catalyst Immunotherapy company joins growing cell & gene therapy community on campusStevenage, UK,…Read More +
ACHILLES THERAPEUTICS LAUNCHED WITH FUNDS OF £13.2 MILLION TO DEVELOP IMMUNOTHERAPIES FOR CANCER Wednesday 5 October, 2016 SYNCONA LLP and CANCER…Read More +
Achilles was founded by world-leading experts in cancer evolution, bioinformatics and the development of cell-based immunotherapies. The company brings together these disciplines to develop next-generation, patient-specific cell therapies that harness the immune system to destroy cancer cells.
Co-founder Charlie Swanton speaks about his career, the advent of immunotherapy and what the Achilles team are looking to achieve.